Leerink Partnrs Weighs in on Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Genmab A/S in a report released on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of $0.43 per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S's FY2025 earnings at $1.59 EPS and FY2026 earnings at $1.99 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

GMAB has been the subject of several other research reports. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. BMO Capital Markets reissued an "outperform" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.17.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded up $0.47 during trading hours on Monday, hitting $22.44. 1,030,388 shares of the company's stock traded hands, compared to its average volume of 1,581,457. The stock has a market capitalization of $14.85 billion, a price-to-earnings ratio of 12.90, a PEG ratio of 2.57 and a beta of 0.96. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88. The company has a fifty day simple moving average of $20.64 and a 200-day simple moving average of $22.97.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its position in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC raised its stake in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC lifted its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC grew its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.